ANNX Share Price Performance
US$5.29
2.94 (125.11%)
76.3% overvalued intrinsic discount
US$3.00
Fair Value
Price US$5.29
AnalystLowTarget US$3.00
Fair ValueUS$3.00
Share Pricen/a
New Narrative • Aug 12
Annexon, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
ANNX Community Narratives
AN
Fair Value
·Fair Value US$3 76.3% overvalued intrinsic discount
Reliance On Single Late-Stage Asset Will Expose Serious Long-Term Revenue And Earnings Risks
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Reliance On Single Late-Stage Asset Will Expose Serious Long-Term Revenue And Earnings Risks
Annexon’s hopes rest heavily on one lead program, so any slowdown from regulators or doctors could leave the company with years of high spending and little to show for it. The bigger question is whether its eye disease trial can prove clear real-world benefit before larger rivals and rising costs squeeze its runway.Read more
AN
US$3
76.3% overvalued intrinsic discount
Fair Value
Profit Margin
17.45%
Future PE
27.52x
Price in 2029
US$0
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Reliance On Single Late-Stage Asset Will Expose Serious Long-Term Revenue And Earnings Risks
Fair Value: US$3 76.3% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Annexon, Inc. Key Details
About ANNX
- Founded
- 2011
- Employees
- 92
- CEO
- WebsiteView website
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington’s disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis. It is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
